Aptose Biosciences reports data from Phase 1/2 TUSCANY trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 05 2025
0mins
Aptose Biosciences TUSCANY Trial Results: Aptose reported promising results from its Phase 1/2 TUSCANY trial for newly diagnosed acute myeloid leukemia (AML) patients using tuspetinib combined with venetoclax and azacitidine, showing safety and antileukemic activity at both 40 mg and 80 mg doses.
Clinical Outcomes and Future Expectations: Several patients achieved complete remission or clinical improvement, particularly those with adverse mutations, indicating that the triplet combination therapy may effectively treat diverse AML populations, with ongoing monitoring of their disease status.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
